RankAlpha logo
Back to Rankings

PAHC

Phibro Animal HealthD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The bull case strengthened after the May 6 print: animal-health sales grew 13%, total sales rose 10%, adjusted EBITDA rose 11%, and management raised FY26 guidance while saying visibility into the rest of the year improved [#8-K-2026-05-06].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -6.9.
What can break
Brazil antimicrobial regulation could disrupt a meaningful slice of the animal-health mix and needs follow-up on scope and duration [#8-K-2026-05-06].
Momentum
2
Value
65
Sentiment
80
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $36.00 · Bull $48.00 · Bear $24.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-31 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $48.50
Why
Momentum2 · Δ7d -0.1
Value65 · Δ7d +0.7
Sentiment80 · Δ7d -6.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
2
34% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-18.9
Value
65
32% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
+1.2
Sentiment
80
33% active weight
Current posture
7d trendSoftening
Δ7d
-6.9
Δ21d
+10.4
Why this grade

Composite grade D. Momentum 1.8 / Value 64.7 / Sentiment 80.3

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.21B
Beta
0.79
Shares Out
40.53M
P/E (TTM)
23.1
P/S (TTM)
1.11
P/FCF (TTM)
104.84
Rev YoY
+39.7%
EPS YoY
+277.6%
Gross Margin
+31.9%
Op Margin
+10.3%
Net Debt
$641.65M
Current Ratio
3.09
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology